![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bioseek | LSE:ATD | London | Ordinary Share | GB0009231639 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMATD
RNS Number : 2161A
Asterand PLC
28 March 2012
Asterand's Subsidiary BioSeek Extends Collaboration with Merck Serono
New Three-Year Deal Provides Merck Serono Expanded Access to BioSeek LLC's BioMAP(R) Platform
SOUTH SAN FRANCISCO, CA, USA (March 28, 2012) - BioSeek, LLC, a subsidiary of Asterand plc (LSE: ATD), a pioneer in the application of predictive human biology to drug discovery, announced today that it has signed a new, three-year collaboration agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany. The new agreement extends and expands the companies' previous three-year agreement from 2009. Under the new research plan, BioSeek will expand the use of its proprietary BioMAP platform to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection and optimization and nomination of candidates for preclinical development at Merck Serono.
Jack Davis, Chairman and Interim Chief Executive Officer of Asterand commented:
"We highly value our long-standing relationship with Merck Serono. The studies carried out by BioSeek for Merck Serono over the past three years have demonstrated that BioMAP Platform can be used to reliably advance promising molecules through preclinical evaluation. Our scientists have worked closely and productively with the Merck Serono team, and we look forward to our continuing and expanding research with them".
BioMAP(R) Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in human pharmacology and toxicology. Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP(R) profiles) that can be compared to a large number of reference profiles in the BioMAP(R) Database. Assessment with BioMAP(R) provides early insight into human pharmacological and toxicological properties of compounds, including on-and off-target effects, dose responses, and the discrimination of closely related compounds.
About BioSeek
BioSeek, LLC, is a wholly owned subsidiary of Asterand plc (LSE: ATD), a leading supplier of high quality human tissue and tissue-based services. BioSeek improves the success rate of pharmaceutical research and development by integrating human biology from the earliest stages of drug discovery onward through its unique BioMAP(R) predictive human-based models. Our mission is to accelerate target discovery and drug compound validation and enable our clients to take safer and more effective drugs into the market.
For more information about Asterand and BioSeek, please visit http://www.asterand.com.
Contacts
BioSeek LLC (Asterand plc) Tel: +1 (650) 416 7629 Ivan Plavec, VP Business Development Daniel Stewart & Company plc Antony Legge Tel: +44 (0) 20 7776 6550 David Hart Paul Shackleton
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAPDXASSAEFF
1 Year Bioseek Chart |
1 Month Bioseek Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions